• Proprietary SOF-VAC^TM asset with potential to make mRNA vaccines safer, better tolerated by patients and more cost-effective to manufacture
• Preclinical first-in-class mRNA technology based on company’s Sofra^TM platform
• Smallest molecule of its type to have demonstrated strong activity against inflammation
• Developed in collaboration with strategic partner Hudson Institute of Medical Research
• Growing worldwide activity in multi-billion mRNA market

A lead candidate has now been selected for further development. Under the ongoing collaboration with the Hudson Institute of Medical Research, the team has synthesised a novel ‘vaccine enhancer’ called SOF-VAC^TM.

This preclinical technology aims to make a broad range of mRNA vaccines safer by reducing inflammation associated with mRNA vaccines. In addition, the technology has the potential to support more cost-effective mRNA vaccine manufacturing.

The team’s recent development work on SOF-VAC^TM has shown strong in vitro and in vivo activity against inflammation. SOF-VAC^TM represents a first-in-class achievement as the smallest known molecule of its type to have demonstrated this activity. The major advantage of such a small molecule is it reduces the risk of off-target effects compared to larger molecules of this type.